Title : Interaction Analysis of MRP1 with Anticancer Drugs Used in Ovarian Cancer: In Silico Approach.

Pub. Date : 2022 Mar 7

PMID : 35330134






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In this study, we utilize homology modelling and molecular docking analysis to determine the binding affinity and the potential interaction sites of MRP1 with Carboplatin, Gemcitabine, Doxorubicin, Paclitaxel, and Topotecan. Carboplatin ATP binding cassette subfamily B member 1 Homo sapiens
2 Paclitaxel has shown the highest binding affinity whereas Carboplatin displayed the lowest affinity to MRP1. Carboplatin ATP binding cassette subfamily B member 1 Homo sapiens
3 Interestingly, our data showed that Carboplatin, Paclitaxel, and Topotecan bind specifically to Asn510 residue in the transmembrane domains 1 of the MRP1. Carboplatin ATP binding cassette subfamily B member 1 Homo sapiens
4 Our results suggest that Carboplatin could be an appropriate therapeutic choice against MRP1 in OC as it couples weakly with Carboplatin. Carboplatin ATP binding cassette subfamily B member 1 Homo sapiens